Ongoing clinical trials are currently assessing novel combinations such as PF-07104091 (CDK2-selective inhibitor) with PF-07220060 (CDK4-selective inhibitor) plus ET in advanced HR+/HER2− breast cancer (NCT05262400). This evidence concerns the gene CDK2 and breast cancer.